SCHEMBL10101376

SCHEMBL10101376

C/C(=N\O)c1ccc(OCCCCCOc2ccc(/C(N)=N\O)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.75
RAB9A P51151 2/20 0.75
NPC1 O15118 1/20 0.75
LMNA P02545 1/20 0.75
TP53 P04637 1/20 0.75
MAPT P10636 1/20 0.75
ALOX15 P16050 1/20 0.75
HSD17B10 Q99714 1/20 0.75
FURIN P09958 1/20 0.56
SLC2A1 P11166 2/20 0.54
PRMT1 Q99873 3/20 0.51
F2 P00734 2/20 0.51
ST14 Q9Y5Y6 2/20 0.51
PLAU P00749 1/20 0.51
PRMT5 O14744 1/20 0.51
SLC22A2 O15244 1/20 0.51
SLC22A1 O15245 1/20 0.51
TMPRSS2 O15393 1/20 0.51
PTP4A3 O75365 1/20 0.51
SLC22A3 O75751 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8739981 1.00 GAA (0.75) GAARAB9ANPC1LMNATP53
Pentamidine Dao SCHEMBL12355833 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
SCHEMBL14599580 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
SCHEMBL14599647 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
Pentamidine Dao SCHEMBL8653348 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
SCHEMBL14599579 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
SCHEMBL14599648 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
Pentamidine Dao SCHEMBL12348101 0.90 GAA (0.84) GAARAB9ANPC1LMNATP53
SCHEMBL8739980 0.86 PRMT1 (0.73) GAARAB9ANPC1LMNATP53
SCHEMBL2368560 0.86 GAA (1.00) GAARAB9ANPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8110583-B2 treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle MERCK PATENT GMBH (DE) 2012-02-07 US disclosed
US-7915416-B2 Tetrahydroquinolines MERCK PATENT GMBH (DE) 2011-03-29 US disclosed
US-7875614-B2 compounds for treatment of tumors MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-7868172-B2 2-(hetero)-aryl substituted tetrahydroquinoline derivatives MERCK PATENT GMBH (DE) 2011-01-11 US disclosed
US-20100120818-A1 SUBSTITUTED TETRAHYDROPYRROLOQUINOLINES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-05-13 US disclosed
US-20100076012-A1 TETRAHYDROQUINOLINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2010-03-25 US disclosed
US-20090118267-A1 INDANES MERCK PATENT GMBH (DE) 2009-05-07 US disclosed
US-20090030028-A1 Tetrahydroquinolines MERCK PATENT GMBH (DE) 2009-01-29 US disclosed
US-20080234299-A1 Quinazolinones MERCK PATENT GMBH (DE) 2008-09-25 US disclosed
US-20080221118-A1 treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle MERCK PATENT GMBH (DE) 2008-09-11 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080194569-A1 Phthalazinones MERCK PATENT GMBH (DE) 2008-08-14 US disclosed
US-20070219246-A1 Dihydrobenzothiophenes MERCK PATENT GMBH (DE) 2007-09-20 US disclosed
US-20070203167-A1 2-(Hetero)-aryl substituted tetrahydrochinoline MERCK PATENT GMBH (DE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194569-A1 Phthalazinones RB1, H1-3, H1-2 GAA 3424/4885RAB9A 1248/4885NPC1 1983/4885
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B GAA 2068/4885RAB9A 261/4885NPC1 3500/4885
US-20090118267-A1 INDANES IDH3A, CYP1A1, CCNT1 GAA 4518/4885RAB9A 2155/4885NPC1 1432/4885
US-20080234299-A1 Quinazolinones H1-3, NDUFS3, CCNT1 GAA 3655/4885RAB9A 229/4885NPC1 2274/4885
US-20100076012-A1 TETRAHYDROQUINOLINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER RECQL, NDUFS3, SDHA GAA 4326/4885RAB9A 1239/4885NPC1 2678/4885
US-20090030028-A1 Tetrahydroquinolines RECQL, QTRT1, NRAS GAA 3810/4885RAB9A 743/4885NPC1 1965/4885
US-20070203167-A1 2-(Hetero)-aryl substituted tetrahydrochinoline NCOR1, CCNT2, NCOR2 GAA 4282/4885RAB9A 1719/4885NPC1 1194/4885
US-20070219246-A1 Dihydrobenzothiophenes CCNT1, CCNT2, TPT1 GAA 3665/4885RAB9A 2614/4885NPC1 3392/4885
US-20100120818-A1 SUBSTITUTED TETRAHYDROPYRROLOQUINOLINES TPD52L2, CCNT1, IDH2 GAA 4657/4885RAB9A 1796/4885NPC1 2665/4885
US-20080221118-A1 treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle CCNE1, CCNA1, CCNT1 GAA 4608/4885RAB9A 3850/4885NPC1 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.